ALK and head and neck squamous cell carcinoma: However, if the identified Cl6 and Cl4 molecular portraits are confirmed, new immunotherapeutic modalities and/or ALK targeted therapy [26] that have never been analyzed in HNSCC, could be offered to patients with high immunoreactivity (Cl6) or defense response status and ALK activation (Cl4).